{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alum+Adjuvant&page=4",
    "query": {
      "intervention": "Alum Adjuvant",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 163,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alum+Adjuvant&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alum+Adjuvant&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T09:26:41.863Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00294047",
      "title": "Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infections, Papillomavirus",
        "Papillomavirus Vaccines"
      ],
      "interventions": [
        {
          "name": "Cervarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "26 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "26 Years and older · Female only"
      },
      "enrollment_count": 5752,
      "start_date": "2006-02-16",
      "completion_date": "2014-01-29",
      "has_results": true,
      "last_update_posted_date": "2020-01-02",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 36,
      "location_summary": "Fountain Valley, California • Aurora, Colorado • Golden, Colorado + 29 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00294047"
    },
    {
      "nct_id": "NCT04368585",
      "title": "Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)",
          "type": "DRUG"
        },
        {
          "name": "20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spero Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-01",
      "completion_date": "2020-08-21",
      "has_results": false,
      "last_update_posted_date": "2020-09-04",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04368585"
    },
    {
      "nct_id": "NCT02661490",
      "title": "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Norovirus"
      ],
      "interventions": [
        {
          "name": "Norovirus GI.1/GII.4 Bivalent VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.9% sodium chloride (saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2016-02-01",
      "completion_date": "2017-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02661490"
    },
    {
      "nct_id": "NCT01097096",
      "title": "Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CAD106",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "Up to 85 Years"
      },
      "enrollment_count": 177,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 5,
      "location_summary": "Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01097096"
    },
    {
      "nct_id": "NCT00001096",
      "title": "A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "QS-21",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rgp120/HIV-1MN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 60,
      "start_date": null,
      "completion_date": "2000-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001096"
    },
    {
      "nct_id": "NCT03776994",
      "title": "Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Encephalitis",
        "Encephalitis, Viral",
        "Infectious Encephalitis",
        "Virus Diseases",
        "Encephalomyelitis, Venezuelan Equine",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Central Nervous System Viral Diseases",
        "Alphavirus Infections",
        "Togaviridae Infections",
        "RNA Virus Infections",
        "Central Nervous System Infections",
        "Encephalomyelitis",
        "Physiological Effects of Drugs",
        "Vaccines",
        "Encephalomyelitis, Equine",
        "Nervous System Diseases"
      ],
      "interventions": [
        {
          "name": "Vaccinations on Day 0, Day 28, and Day 140",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "SRI International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2018-07-17",
      "completion_date": "2021-04",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 1,
      "location_summary": "Plymouth, Michigan",
      "locations": [
        {
          "city": "Plymouth",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776994"
    },
    {
      "nct_id": "NCT01847027",
      "title": "Exercise and NutraStem (NT-020): Effects on Stem Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Stem Cell Proliferation"
      ],
      "interventions": [
        {
          "name": "NutraStem",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Texas Health Science Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "50 Years to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-04",
      "completion_date": "2017-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-05-29",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847027"
    },
    {
      "nct_id": "NCT02117934",
      "title": "Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HEPLISAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8374,
      "start_date": "2014-04",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117934"
    },
    {
      "nct_id": "NCT05349617",
      "title": "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chikungunya Virus"
      ],
      "interventions": [
        {
          "name": "CHIKV VLP/adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2022-05-12",
      "completion_date": "2023-08-08",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Miami Lakes, Florida • St. Petersburg, Florida + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05349617"
    },
    {
      "nct_id": "NCT00001053",
      "title": "A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV p17/p24:Ty-VLP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": null,
      "completion_date": "1996-03",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-07T09:26:41.863Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001053"
    }
  ]
}